This brief highlights some key steps and considerations for biopharmaceutical developers of novel, high-value therapies seeking to successfully implement CMS’s Multiple Best Price rule. The rule, which went into effect in 2022, addresses the challenge of establishing a Medicaid best price under a Value-Based Contract.
Share the research